Item Number | Policy/Procedure | Date Posted | Comment Period Closed | Status | Document Links |
---|---|---|---|---|---|
2023-HBL-1102 | Allogen, Xeno, Synthc and Composite Products for Wound Healing and Soft Tissue Grafting | 9/12/23 | 10/27/23 | Approved | Allogen, Xeno, Synthc and Composite Products for Wound Healing and Soft Tissue Grafting |
2023-HBL-1201 | Vena Cava Filters | 9/12/23 | 10/27/23 | Approved | Vena Cava Filters |
2023-LHCC-1211 | Reduction Mammoplasty and Gynecomastia Surgery | 9/12/23 | 10/27/23 | Approved | Reduction Mammoplasty and Gynecomastia Surgery |
2023-LHCC-1224 | Fetal Surgery in Utero | 9/12/23 | 10/27/23 | Approved | Fetal Surgery in Utero |
2023-HBL-1238 | Upper Gastrointestinal Endoscopy in Adults | 9/12/23 | 10/27/23 | Approved | Upper Gastrointestinal Endoscopy in Adults |
2023-HBL-1346 | Virtual Reality-Assisted Therapy Systems | 9/12/23 | 10/27/23 | Approved | Virtual Reality-Assisted Therapy Systems |
2023-LHCC-1452 | Caudal or Interlaminar Epidural Steroid Injections | 9/12/23 | 10/27/23 | Approved | Caudal or Interlaminar Epidural Steroid Injections |
2023-LHCC-1454 | Facet Joint Interventions | 9/12/23 | 10/27/23 | Approved | Facet Joint Interventions |
2023-LHCC-1456 | Fecal Incontinence Treatments | 9/12/23 | 10/27/23 | Approved | Fecal Incontinence Treatments |
2023-LHCC-1457 | Neuromuscular Electrical Stimulation | 9/12/23 | 10/27/23 | Approved | Neuromuscular Electrical Stimulation |
2023-LHCC-1504 | Reporting the Global Maternity Package | 9/12/23 | 10/27/23 | Approved | Reporting the Global Maternity Package |
2023-LHCC-1712 | Transportation for SDOH | 9/12/23 | 10/27/23 | Approved | Transportation for SDOH |
2023-LHCC-1743 | Hospice Services | 9/12/23 | 10/27/23 | Approved | Hospice Services |
2023-LHCC-1746 | Total Artificial Heart | 9/12/23 | 10/27/23 | Approved | Total Artificial Heart |
2023-LHCC-1840 | Cochlear Implants and Replacements | 9/12/23 | 10/27/23 | Approved | Cochlear Implants and Replacements |
2023-UHC-1939 | Beds and Mattresses | 9/12/23 | 10/27/23 | Approved | Beds and Mattresses |
2023-HUM-2173 | Genetic Testing | 9/12/23 | 10/27/23 | Approved | Genetic Testing |
2023-HUM-2180 | Homebuilders | 9/12/23 | 10/27/23 | Approved | Homebuilders |
2023-HBL-2181 | Prior Authorization Changes UM AROW 3959 | 9/12/23 | 10/27/23 | Approved | Prior Authorization Changes UM AROW 3959 |
2023-HBL-2182 | Prior Authorization Changes UM AROW 4073 | 9/12/23 | 10/27/23 | Approved | Prior Authorization Changes UM AROW 4073 |
2023-HBL-2185 | Technology Assisted Surgery Procedures | 9/12/23 | 10/27/23 | Approved | Technology Assisted Surgery Procedures |
2023-HBL-2191 | Digital Therapy Devices for Treatment of Amblyopia | 9/12/23 | 10/27/23 | Approved | Digital Therapy Devices for Treatment of Amblyopia |
2023-ACLA-2200 | Psychiatric Residential Treatment | 9/12/23 | 10/27/23 | Approved | Psychiatric Residential Treatment |
2023-ACLA-2202 | Crisis Stabilization – Adults | 9/12/23 | 10/27/23 | Approved | Crisis Stabilization – Adults |
2023-ACLA-2203 | Crisis Stabilization – Pediatrics | 9/12/23 | 10/27/23 | Approved | Crisis Stabilization – Pediatrics |
2023-ACLA-2204 | Infertility Diagnosis and Treatment | 9/12/23 | 10/27/23 | Approved | Infertility Diagnosis and Treatment |
2023-HBL-2214 | Diagnostic Fibrotic Flexible Laryngoscopy | 9/12/23 | 10/27/23 | Approved | Diagnostic Fibrotic Flexible Laryngoscopy |
2023-LDH-14 | MCO Manual > Part 9: Provider Network > Primary Care > Enrollee Reassignment Policy (Effective date = 11/15/2023) | 8/25/23 | 10/9/23 | Pending | Enrollee Reassignment Policy |
2023-LHCC-1471 | 24 Hour Payment Rule | 8/25/23 | 10/9/23 | Approved | 24 Hour Payment Rule |
2023-LHCC-1496 | Hospital Visit Codes Billed with Labs | 8/25/23 | 10/9/23 | Approved | Hospital Visit Codes Billed with Labs |
2023-LHCC-1503 | Inpatient Only Procedures | 8/25/23 | 10/9/23 | Approved | Inpatient Only Procedures |
2023-UHC-1523 | Facet Joint and Medial Branch Block Injections for Spinal Pain | 8/25/23 | 10/9/23 | Approved | Facet Joint and Medial Branch Block Injections for Spinal Pain |
2023-LHCC-1833 | Assertive Community Treatment (ACT) | 8/25/23 | 10/9/23 | Approved | Assertive Community Treatment (ACT) |
2023-ABH-1943 | Member Incentives | 8/25/23 | 10/9/23 | Approved | Member Incentives |
2023-LHCC-2184 | Organizational Assessment and Reassessment | 8/25/23 | 10/9/23 | Complete | Organizational Assessment and Reassessment |
2023-UHC-2186 | Left Atrial Appendage Closure | 8/25/23 | 10/9/23 | Approved | Left Atrial Appendage Closure |
2023-HBL-2187 | Level of Care for Musculoskeletal Surgery and Procedures | 8/25/23 | 10/9/23 | Approved | Level of Care for Musculoskeletal Surgery and Procedures |
2023-UHC-2188 | Mandatory Medicaid Coverage of Routine Patient Costs in Qualifying Clinical Trials | 8/25/23 | 10/9/23 | Approved | Mandatory Medicaid Coverage of Routine Patient Costs in Qualifying Clinical Trials |
2023-HBL-2189 | Ultrasound Bone Growth Stimulation | 8/25/23 | 10/9/23 | Approved | Ultrasound Bone Growth Stimulation |
2023-HBL-2190 | Myringotomy and Tympsnodtomy Tube Insertion | 8/25/23 | 10/9/23 | Approved | Myringotomy and Tympsnodtomy Tube Insertion |
2023-HBL-2192 | Magnetic Source Imaging and Magnetoencephalography | 8/25/23 | 10/9/23 | Approved | Magnetic Source Imaging and Magnetoencephalography |
2023-HBL-2193 | Vertical Prosthetic Titanium | 8/25/23 | 10/9/23 | Approved | Vertical Prosthetic Titanium |
2023-HBL-2194 | Surgical Treatment for Dupuytren's Contracture | 8/25/23 | 10/9/23 | Approved | Surgical Treatment for Dupuytren's Contracture |
2023-HBL-2195 | Prostate Specific Antigen Testing | 8/25/23 | 10/9/23 | Approved | Prostate Specific Antigen Testing |
2023-HBL-2196 | Intraocular Anterior Segment Aqueous Drainage Devices (without extraocular reservoirs) | 8/25/23 | 10/9/23 | Approved | Intraocular Anterior Segment Aqueous Drainage Devices (without extraocular reservoirs) |
2023-HBL-2197 | Auditory Brainstem Response (ABR) and Evoked Emissions | 8/25/23 | 10/9/23 | Approved | Auditory Brainstem Response (ABR) and Evoked Emissions |
2023-HBL-2198 | Diagnostic Hysteroscopy for Infertility | 8/25/23 | 10/9/23 | Approved | Diagnostic Hysteroscopy for Infertility |
2023-UHC-379 | Brow Ptosis and Eyelid Repair | 8/25/23 | 10/9/23 | Approved | Brow Ptosis and Eyelid Repair |
2023-UHC-492 | Surgical and Ablative Procedures for Venous Insufficiency and Varicose Veins | 8/25/23 | 10/9/23 | Approved | Surgical and Ablative Procedures for Venous Insufficiency and Varicose Veins |
2023-UHC-509 | Breast Reconstruction | 8/25/23 | 10/9/23 | Approved | Breast Reconstruction |
2023-UHC-558 | Surgery of the Knee | 8/25/23 | 10/9/23 | Approved | Surgery of the Knee |
2023-UHC-561 | Cognitive Rehabilitation | 8/25/23 | 10/9/23 | Approved | Cognitive Rehabilitation |
2023-HBL-985 | Small Joint Surgery Criteria | 8/25/23 | 10/9/23 | Approved | Small Joint Surgery Criteria |
2023-HBL-1023 | Genetic Testing for Inherited Diseases | 8/25/23 | 10/9/23 | Approved | Genetic Testing for Inherited Diseases |
2023-HBL-1026 | Gene Expression Profiling for Managing Breast Cancer Treatment | 8/25/23 | 10/9/23 | Approved | Gene Expression Profiling for Managing Breast Cancer Treatment |
2023-HBL-1042 | Ablative Techniques as a Treatment for Barrett's Esophagus | 8/25/23 | 10/9/23 | Approved | Ablative Techniques as a Treatment for Barrett's Esophagus |
2023-HBL-1091 | Transcatheter Heart Valve Procedures | 8/25/23 | 10/9/23 | Approved | Transcatheter Heart Valve Procedures |
2023-HBL-1123 | Extracorporeal Shock Wave Therapy (ESWT) for Musculoskeletal Conditions and Soft Tissue Wounds | 8/25/23 | 10/9/23 | Approved | Extracorporeal Shock Wave Therapy (ESWT) for Musculoskeletal Conditions and Soft Tissue Wounds |
2023-HBL-1203 | CMA for Developmental Delay | 8/25/23 | 10/9/23 | Approved | CMA for Developmental Delay |
2023-HBL-1221 | Diagnostic Infertility Surgery | 8/25/23 | 10/9/23 | Approved | Diagnostic Infertility Surgery |
2023-HBL-1260 | Circulating Tumor DNA Panel Testing (Liquid Biopsy) | 8/25/23 | 10/9/23 | Approved | Circulating Tumor DNA Panel Testing (Liquid Biopsy) |
2023-HBL-1309 | BRCA Genetic Testing | 8/25/23 | 10/9/23 | Approved | BRCA Genetic Testing |
2023-HBL-1320 | Joint Surgery | 8/25/23 | 10/9/23 | Approved | Joint Surgery |
2023-HBL-1323 | Hyperbaric Oxygen Therapy | 8/25/23 | 10/9/23 | Approved | Hyperbaric Oxygen Therapy |
2023-UHC-1426 | Genetic Testing for Cardiac Disease | 8/25/23 | 10/9/23 | Approved | Genetic Testing for Cardiac Disease |
2023-HBL-1463 | Nucleic Acid Amplification Tests Using Algorithmic Analysis for the Diagnosis of Bacterial Vaginosis | 8/25/23 | 10/9/23 | Approved | Nucleic Acid Amplification Tests Using Algorithmic Analysis for the Diagnosis of Bacterial Vaginosis |
2023-UHC-559 | Implantable Beta-Emitting Microspheres | 8/8/23 | 9/22/23 | Approved | Implantable Beta-Emitting Microspheres |
2023-LHCC-1479 | High Complexity Medical Decision-Making | 8/8/23 | 9/22/23 | Approved | High Complexity Medical Decision-Making |
2023-LHCC-1500 | Pulse Oximetry with Office Visits | 8/8/23 | 9/22/23 | Approved | Pulse Oximetry with Office Visits |
2023-LHCC-1701 | Outpatient Testing for DOA (Drugs of Use) | 8/8/23 | 9/22/23 | Approved | Outpatient Testing for DOA (Drugs of Use) |
2023-LHCC-1705 | Invasive and Non-Invasive Home Ventilator | 8/8/23 | 9/22/23 | Approved | Invasive and Non-Invasive Home Ventilator |
2023-ACLA-1870 | Behavioral Health Crisis Care | 8/8/23 | 9/22/23 | Approved | Behavioral Health Crisis Care |
2023-LHCC-1908 | Community Brief Crisis Support | 8/8/23 | 9/22/23 | Approved | Community Brief Crisis Support |
2023-UHC-1941 | Louisiana ABA Policy | 8/8/23 | 9/22/23 | Approved | Louisiana ABA Policy |
2023-HUM-2161 | Intrauterine Device | 8/8/23 | 9/22/23 | Approved | Intrauterine Device |
2023-HUM-2162 | Nexplanon, Etonogestrel Implant | 8/8/23 | 9/22/23 | Approved | Nexplanon, Etonogestrel Implant |
2023-HUM-2167 | Duplicate Diagnosis | 8/8/23 | 9/22/23 | Approved | Duplicate Diagnosis |
2023-HUM-2168 | Intrauterine Contraceptive Systems and Implants | 8/8/23 | 9/22/23 | Approved | Intrauterine Contraceptive Systems and Implants |
2023-HUM-2169 | Assistant Surgeon Modifiers | 8/8/23 | 9/22/23 | Approved | Assistant Surgeon Modifiers |
2023-HUM-2174 | Levonorgestrl-releasing intrauterine contraceptive | 8/8/23 | 9/22/23 | Approved | Levonorgestrl-releasing intrauterine contraceptive |
2023-HUM-2177 | Nexplanon | 8/8/23 | 9/22/23 | Approved | Nexplanon |
2023-LDH-13 | State Directed Payment Program Manual | 8/2/23 | 9/16/23 | Pending | State Directed Payment Program Manual |
2023-LDH-12 | MCO Manual > Part 4: Services > Medical Transportation (Proposed effective date = 10/23/2023) | 8/2/23 | 9/16/23 | Pending | Medical Transportation |
2023-HBL-819 | HBL Provider Manual | 8/25/23 | 10/9/23 | Withdrawn | HBL Provider Manual |
2023-LHCC-1491 | NCCI Unbundling | 7/27/23 | 9/10/23 | Complete | NCCI Unbundling |
2023-LHCC-1494 | Assistant Surgeon | 7/27/23 | 9/10/23 | Complete | Assistant Surgeon |
2023-LHCC-1497 | Modifier to Procedure Code Validation | 7/27/23 | 9/10/23 | Complete | Modifier to Procedure Code Validation |
2023-LHCC-1501 | Distinct Procedural Modifiers | 7/27/23 | 9/10/23 | Complete | Distinct Procedural Modifiers |
2023-LHCC-1502 | Professional Services Billed with Labs | 7/27/23 | 9/10/23 | Complete | Professional Services Billed with Labs |
2023-LHCC-1505 | Moderate Conscious Sedation | 7/27/23 | 9/10/23 | Complete | Moderate Conscious Sedation |
2023-LHCC-1507 | Clinical Validation of Modifier 59 | 7/27/23 | 9/10/23 | Complete | Clinical Validation of Modifier 59 |
2023-LHCC-1508 | Intravenous Hydration | 7/27/23 | 9/10/23 | Complete | Intravenous Hydration |
2023-LHCC-1509 | Clinical Validation of Modifier 25 | 7/27/23 | 9/10/23 | Complete | Clinical Validation of Modifier 25 |
2023-LHCC-1510 | EM Bundling with Labs and Radiology | 7/27/23 | 9/10/23 | Complete | EM Bundling with Labs and Radiology |
2023-LHCC-1213 | Sacroiliac Joint Fusion | 7/26/23 | 9/10/23 | Approved | Sacroiliac Joint Fusion |
2023-LHCC-1270 | Urinary Incontinence Devices and Treatments | 7/26/23 | 9/10/23 | Approved | Urinary Incontinence Devices and Treatments |
2023-LHCC-1272 | PCR Respiratory Viral Panel Testing | 7/26/23 | 9/10/23 | Approved | PCR Respiratory Viral Panel Testing |
2023-LHCC-1388 | Code Editing Overview | 7/26/23 | 9/10/23 | Complete | Code Editing Overview |
2023-LHCC-1412 | Clinical Trials | 7/26/23 | 9/10/23 | Approved | Clinical Trials |
2023-LHCC-1413 | Discography | 7/26/23 | 9/10/23 | Approved | Discography |
2023-LHCC-1472 | Transparency Policy: Place of Service Mismatch | 7/26/23 | 9/10/23 | Complete | Transparency Policy: Place of Service Mismatch |
2023-LHCC-1487 | Sleep Studies Place of Service | 7/26/23 | 9/10/23 | Complete | Sleep Studies Place of Service |
2023-LHCC-1495 | Add-on Code Billed without Primary Code | 7/26/23 | 9/10/23 | Complete | Add-on Code Billed without Primary Code |
2023-LHCC-1498 | Professional Component Modifier | 7/26/23 | 9/10/23 | Complete | Professional Component Modifier |
2023-LHCC-1499 | Clean Claims Policy | 7/26/23 | 9/10/23 | Complete | Clean Claims Policy |
2023-LHCC-1506 | Never Paid Events | 7/26/23 | 9/10/23 | Complete | Never Paid Events |
2023-LHCC-1511 | Unlisted Procedure Codes | 7/26/23 | 9/10/23 | Complete | Unlisted Procedure Codes |
2023-LHCC-1512 | Maximum Units of Service | 7/26/23 | 9/10/23 | Complete | Maximum Units of Service |
2023-ACLA-1937 | ILOS - Hospital Based Care Coordination | 7/26/23 | 9/10/23 | Approved | ILOS - Hospital Based Care Coordination |
2023-ACLA-1942 | Duplicate Claim | 7/26/23 | 9/10/23 | Approved | Duplicate Claim |
2023-LHCC-2178 | Omisirge (Omidubicel) | 7/26/23 | 9/10/23 | Approved | Omisirge (Omidubicel) |
2023-LHCC-2179 | Rapid Whole Genome Sequencing of Critically Ill Infants | 7/26/23 | 9/10/23 | Approved | Rapid Whole Genome Sequencing of Critically Ill Infants |
2023-LDH-11 | MCO Manual > Part 4: Services > Pharmacy > Prior Authorization (Proposed effective date = 10/16/2023) | 7/26/23 | 9/9/23 | Approved | Pharmacy Prior Authorization |
2023-UHC-222 | Skin and Soft Tissue Substitutes | 7/26/23 | 9/9/23 | Approved | Skin and Soft Tissue Substitutes |
2023-UHC-476 | Cytological Examination of Breast Fluids for Cancer Screening or Diagnosis | 7/26/23 | 9/9/23 | Approved | Cytological Examination of Breast Fluids for Cancer Screening or Diagnosis |
2023-UHC-582 | Cosmetic and Reconstructive Procedures | 7/26/23 | 9/9/23 | Approved | Cosmetic and Reconstructive Procedures |
2023-UHC-794 | Noncontact Warming Therapy, Ultrasound therapy and Fluorescence Imaging for Wounds | 7/26/23 | 9/9/23 | Approved | Noncontact Warming Therapy, Ultrasound therapy and Fluorescence Imaging for Wounds |
2023-LHCC-934 | BH Provider Quality Program | 7/26/23 | 9/9/23 | Approved | BH Provider Quality Program |
2023-ABH-1007 | BH Provider Monitoring Strategy | 7/26/23 | 9/9/23 | Approved | BH Provider Monitoring Strategy |
2023-HBL-1319 | Imaging of the Extremities | 7/26/23 | 9/9/23 | Approved | Imaging of the Extremities |
2023-HBL-1321 | Vascular Imaging | 7/26/23 | 9/9/23 | Approved | Vascular Imaging |
2023-HBL-1322 | Imaging of the Spine | 7/26/23 | 9/9/23 | Approved | Imaging of the Spine |
2023-HBL-1325 | Sleep Disorder Management | 7/26/23 | 9/9/23 | Approved | Sleep Disorder Management |
2023-UHC-1404 | Breast Imaging for Screening and Diagnosing Cancer | 7/26/23 | 9/9/23 | Approved | Breast Imaging for Screening and Diagnosing Cancer |
2023-UHC-1419 | Carrier Testing for Genetic Diseases | 7/26/23 | 9/9/23 | Approved | Carrier Testing for Genetic Diseases |
2023-HBL-1749 | Gene Therapy for Hemophilia | 7/26/23 | 9/9/23 | Approved | Gene Therapy for Hemophilia |
2023-ACLA-1867 | Psychosocial Rehabilitation Services for Children, Adolescents and Adults | 7/26/23 | 9/9/23 | Approved | Psychosocial Rehabilitation Services for Children, Adolescents and Adults |
2023-LHCC-1947 | ADHD | 7/26/23 | 9/9/23 | Approved | ADHD |
2023-LHCC-1959 | BH Treatment Documentation Requirements | 7/26/23 | 9/9/23 | Approved | BH Treatment Documentation Requirements |
2023-Humana-2163 | Etonogestrel (contraceptive) implant system | 7/26/23 | 9/9/23 | Approved | Etonogestrel (contraceptive) implant system |
2023-LDH-10 | MCO Manual > Part 4: Services > Professional Services > Telemedicine/Telehealth (Proposed effective date = 10/11/2023) | 7/21/23 | 9/3/23 | Pending | Telemedicine/Telehealth |
2023-LDH-9 | MCO Manual > Part 4: Services > Hospital Services > General Policies > Inpatient vs. Outpatient Services (Proposed effective date = 10/11/2023) | 7/21/23 | 9/3/23 | Pending | Inpatient vs. Outpatient Services |
2023-HBL-2158 | Human Chorionic Gonadotrophin Testing | 7/17/23 | 8/31/23 | Approved | Human Chorionic Gonadotrophin Testing |
2023-HBL-2157 | Outpatient Alpha-Fetoprotein Testing | 7/17/23 | 8/31/23 | Approved | Outpatient Alpha-Fetoprotein Testing |
2023-HBL-2156 | Balloon Dilation of the Eustachian Tubes | 7/17/23 | 8/31/23 | Approved | Balloon Dilation of the Eustachian Tubes |
2023-LHCC-2153 | Pharmacy Lock-In Program | 7/17/23 | 8/31/23 | Complete | Pharmacy Lock-In Program |
2023-ACLA-2137 | Continuous Glucose Monitoring | 7/17/23 | 8/31/23 | Approved | Continuous Glucose Monitoring |
2023-ACLA-1989 | Sleep Apnea Treatment Program Exclusions | 7/17/23 | 8/31/23 | Approved | Sleep Apnea Treatment Program Exclusions |
2023-ACLA-1981 | Stimulators - Non-Spinal Electrical Osteogenesis Stimulator | 7/17/23 | 8/31/23 | Approved | Stimulators - Non-Spinal Electrical Osteogenesis Stimulator |
2023-LHCC-1938 | Continuity & Coordination Between Medical and Behavioral Health Care | 7/17/23 | 8/31/23 | Approved | Continuity & Coordination Between Medical and Behavioral Health Care |
2023-HBL-1783 | Mechanical Embolectomy for Treatment of Stroke | 7/17/23 | 8/31/23 | Approved | Mechanical Embolectomy for Treatment of Stroke |
2023-HBL-1303 | Thyroid Testing | 7/17/23 | 8/31/23 | Approved | Thyroid Testing |
2023-HBL-1061 | Venous Angioplasty with or without Stent Placement or Venous Stent Alone | 7/17/23 | 8/31/23 | Approved | Venous Angioplasty with or without Stent Placement or Venous Stent Alone |
2023-LHCC-896 | Physician Incentive Plan | 7/17/23 | 8/31/23 | Approved | Physician Incentive Plan |
2023-ACLA-2133 | DME Prior Authorization Revisions (982 codes) | 7/7/23 | 8/21/23 | Approved | DME Prior Authorization Revisions (982 codes) |
2023-ACLA-2133 | Professional Services Prior Authorization Revisions (678 codes) | 7/7/23 | 8/21/23 | Approved | Professional Services Prior Authorization Revisions (678 codes) |
2023-ACLA-2142 | Genetic Testing for Carrier Status | 7/5/23 | 8/19/23 | Approved | Genetic Testing for Carrier Status |
2023-ACLA-2143 | Genetic Testing for Known Familial Mutations | 7/5/23 | 8/19/23 | Approved | Genetic Testing for Known Familial Mutations |
2023-ACLA-2144 | Genetic Testing for Non-Medical Purposes | 7/5/23 | 8/19/23 | Approved | Genetic Testing for Non-Medical Purposes |
2023-ACLA-2145 | Genetic Testing for Variants of Uncertain Clinical Significance | 7/5/23 | 8/19/23 | Approved | Genetic Testing for Variants of Uncertain Clinical Significance |
2023-ACLA-2146 | Genetic Testing for Prenatal Screening and Diagnostic Testing | 7/5/23 | 8/19/23 | Approved | Genetic Testing for Prenatal Screening and Diagnostic Testing |
2023-ACLA-2147 | Genetic Testing for the Screening, Diagnosis, and Monitoring of Cancer | 7/5/23 | 8/19/23 | Approved | Genetic Testing for the Screening, Diagnosis, and Monitoring of Cancer |
2023-ACLA-2148 | Genetic Testing to Diagnose Non-Cancer Conditions | 7/5/23 | 8/19/23 | Approved | Genetic Testing to Diagnose Non-Cancer Conditions |
2023-ACLA-2149 | Genetic Testing to Predict Disease Risk | 7/5/23 | 8/19/23 | Approved | Genetic Testing to Predict Disease Risk |
2023-ACLA-2150 | Hereditary (Germline) Testing After Tumor (Somatic) Testing | 7/5/23 | 8/19/23 | Approved | Hereditary (Germline) Testing After Tumor (Somatic) Testing |
2023-ACLA-2151 | Investigational and Experimental laboratory Testing | 7/5/23 | 8/19/23 | Approved | Investigational and Experimental laboratory Testing |
2023-ACLA-2152 | Pharmacogenomic Testing for Drug Toxicity and Response | 7/5/23 | 8/19/23 | Approved | Pharmacogenomic Testing for Drug Toxicity and Response |
2023-LHCC-1167 | DME Clinical Policy | 7/5/23 | 8/19/23 | Approved | DME Clinical Policy |
2023-LHCC-1218 | Ventricular Assist Devices | 7/5/23 | 8/19/23 | Approved | Ventricular Assist Devices |
2023-HBL-1301 | Sacroiliac Joint Fusion | 7/5/23 | 8/19/23 | Approved | Sacroiliac Joint Fusion |
2023-HBL-1324 | Spine Surgery | 7/5/23 | 8/19/23 | Approved | Spine Surgery |
2023-LHCC-1357 | Intestinal and Multivisceral Transplant | 7/5/23 | 8/19/23 | Approved | Intestinal and Multivisceral Transplant |
2023-ACLA-1370 | EPSDT PCS 1511-04 | 7/5/23 | 8/19/23 | Approved | EPSDT PCS 1511-04 |
2023-LHCC-1382 | Lysis of Epidural Lesions | 7/5/23 | 8/19/23 | Approved | Lysis of Epidural Lesions |
2023-LHCC-1383 | Disc Decompression Procedures | 7/5/23 | 8/19/23 | Approved | Disc Decompression Procedures |
2023-LHCC-1387 | Percutaneous LAAD Stroke Prevention | 7/5/23 | 8/19/23 | Approved | Percutaneous LAAD Stroke Prevention |
2023-LHCC-1917 | Repair of Nasal Valve Compromise | 7/5/23 | 8/19/23 | Approved | Repair of Nasal Valve Compromise |
2023-ACLA-1984 | Oral Appliances for the Treatment of OSA | 7/5/23 | 8/19/23 | Approved | Oral Appliances for the Treatment of OSA |
2023-ACLA-1998 | Neurological Considerations | 7/5/23 | 8/19/23 | Approved | Neurological Considerations |
2023-ACLA-2132 | Spinal Muscular Atrophy Testing | 7/5/23 | 8/19/23 | Approved | Spinal Muscular Atrophy Testing |
2023-ACLA-2134 | Sleep Disordered Breathing Diagnosis and Treatment, Diagnostic Testing Pre- and Post-Hypoglossal nerve Stimulator Implantation | 7/5/23 | 8/19/23 | Approved | Sleep Disordered Breathing Diagnosis and Treatment, Diagnostic Testing Pre- and Post-Hypoglossal nerve Stimulator Implantation |
2023-ACLA-2135 | Ataxia-Telangiectasia Genetic Testing | 7/5/23 | 8/19/23 | Approved | Ataxia-Telangiectasia Genetic Testing |
2023-ACLA-2136 | Polymerase Gamma (POLG) Related Disorders Genetic Testing | 7/5/23 | 8/19/23 | Approved | Polymerase Gamma (POLG) Related Disorders Genetic Testing |
2023-ACLA-2138 | Confirmatory Genetic Testing | 7/5/23 | 8/19/23 | Approved | Confirmatory Genetic Testing |
2023-ACLA-2139 | Genetic Presymptomatic and Predictive Testing for Adult-Onset conditional in Minors | 7/5/23 | 8/19/23 | Approved | Genetic Presymptomatic and Predictive Testing for Adult-Onset conditional in Minors |
2023-ACLA-2140 | Genetic Testing by Multigene Panels | 7/5/23 | 8/19/23 | Approved | Genetic Testing by Multigene Panels |
2023-ACLA-2141 | Genetic Testing for Cancer susceptibility and Hereditary Cancer syndromes | 7/5/23 | 8/19/23 | Approved | Genetic Testing for Cancer susceptibility and Hereditary Cancer syndromes |
2023-ACLA-2112 | Oncotype DX Breast DCIS | 6/29/23 | 8/13/23 | Approved | Oncotype DX Breast DCIS |
2023-ACLA-2113 | Oncotype DX for Breast Cancer Prognosis | 6/29/23 | 8/13/23 | Approved | Oncotype DX for Breast Cancer Prognosis |
2023-ACLA-2114 | Oncotype DX for Colorectal Cancer Recurrence risk | 6/29/23 | 8/13/23 | Approved | Oncotype DX for Colorectal Cancer Recurrence risk |
2023-ACLA-2115 | Oncotype DX for Prostate Cancer | 6/29/23 | 8/13/23 | Approved | Oncotype DX for Prostate Cancer |
2023-ACLA-2116 | OVA1 | 6/29/23 | 8/13/23 | Approved | OVA1 |
2023-ACLA-2117 | PancraGEN | 6/29/23 | 8/13/23 | Approved | PancraGEN |
2023-ACLA-2118 | Pathology Testing with Mohs Micrographic Surgery | 6/29/23 | 8/13/23 | Approved | Pathology Testing with Mohs Micrographic Surgery |
2023-ACLA-2119 | CA3 Testing for Prostate Cancer | 6/29/23 | 8/13/23 | Approved | CA3 Testing for Prostate Cancer |
2023-ACLA-2120 | Peutz-Jeghers Syndrome Genetic Testing | 6/29/23 | 8/13/23 | Approved | Peutz-Jeghers Syndrome Genetic Testing |
2023-ACLA-2121 | Prenatal Aneuploidy FISH Testing | 6/29/23 | 8/13/23 | Approved | Prenatal Aneuploidy FISH Testing |
2023-ACLA-2122 | Prenatal Maternal Serum Screening | 6/29/23 | 8/13/23 | Approved | Prenatal Maternal Serum Screening |
2023-ACLA-2123 | Prolaris | 6/29/23 | 8/13/23 | Approved | Prolaris |
2023-ACLA-2124 | Prosigna Breast Cancer Prognostic Gene Signature Assay | 6/29/23 | 8/13/23 | Approved | Prosigna Breast Cancer Prognostic Gene Signature Assay |
2023-ACLA-2125 | PTEN Hamartoma Tumor Syndromes Genetic Testing | 6/29/23 | 8/13/23 | Approved | PTEN Hamartoma Tumor Syndromes Genetic Testing |
2023-ACLA-2126 | Rett syndrome Genetic Testing | 6/29/23 | 8/13/23 | Approved | Rett syndrome Genetic Testing |
2023-ACLA-2127 | SARS-CoV-2 (COVID-19) | 6/29/23 | 8/13/23 | Approved | SARS-CoV-2 (COVID-19) |
2023-ACLA-2128 | SelectMDx | 6/29/23 | 8/13/23 | Approved | SelectMDx |
2023-ACLA-2129 | SEPT9 Methylation Analysis for colorectal Cancer | 6/29/23 | 8/13/23 | Approved | SEPT9 Methylation Analysis for colorectal Cancer |
2023-ACLA-2130 | Somatic Mutation Testing-Hematological Malignancies | 6/29/23 | 8/13/23 | Approved | Somatic Mutation Testing-Hematological Malignancies |
2023-ACLA-2131 | Somatic Mutation Testing Solid Tumors | 6/29/23 | 8/13/23 | Approved | Somatic Mutation Testing Solid Tumors |
2023-ACLA-2092 | Cologuard Screening for Colorectal Cancer | 6/28/23 | 8/12/23 | Approved | Cologuard Screening for Colorectal Cancer |
2023-ACLA-2093 | ConfirmMDx for Prostate Cancer Risk | 6/28/23 | 8/12/23 | Approved | ConfirmMDx for Prostate Cancer Risk |
2023-ACLA-2094 | Cxbladder | 6/28/23 | 8/12/23 | Approved | Cxbladder |
2023-ACLA-2095 | Cystic fibrosis Testing | 6/28/23 | 8/12/23 | Approved | Cystic fibrosis Testing |
2023-ACLA-2096 | Decipher Prostate Cancer classifier | 6/28/23 | 8/12/23 | Approved | Decipher Prostate Cancer classifier |
2023-ACLA-2097 | DecisionDx Uveal Melanoma | 6/28/23 | 8/12/23 | Approved | DecisionDx Uveal Melanoma |
2023-ACLA-2098 | Dentatorubral-Pallidoluysian Atrophy Genetic Testing | 6/28/23 | 8/12/23 | Approved | Dentatorubral-Pallidoluysian Atrophy Genetic Testing |
2023-ACLA-2099 | DermTech Pigmented Lesion Assay | 6/28/23 | 8/12/23 | Approved | DermTech Pigmented Lesion Assay |
2023-ACLA-2100 | Dilated Cardiomyopathy Genetic Testing | 6/28/23 | 8/12/23 | Approved | Dilated Cardiomyopathy Genetic Testing |
2023-ACLA-2101 | Duchenne and Becker Muscular Dystrophy Genetic Testing | 6/28/23 | 8/12/23 | Approved | Duchenne and Becker Muscular Dystrophy Genetic Testing |
2023-ACLA-2102 | Early Onset Familial Alzheimer disease Genetic Testing | 6/28/23 | 8/12/23 | Approved | Early Onset Familial Alzheimer disease Genetic Testing |
2023-ACLA-2103 | Ehlers-Danlos Syndrome Genetic Testing | 6/28/23 | 8/12/23 | Approved | Ehlers-Danlos Syndrome Genetic Testing |
2023-ACLA-2104 | EndoPredict for Breast Cancer Prognosis | 6/28/23 | 8/12/23 | Approved | EndoPredict for Breast Cancer Prognosis |
2023-ACLA-2105 | Epilepsy Genetic Testing | 6/28/23 | 8/12/23 | Approved | Epilepsy Genetic Testing |
2023-ACLA-2106 | Exome Sequencing | 6/28/23 | 8/12/23 | Approved | Exome Sequencing |
2023-ACLA-2107 | Expanded Carrier Screening Panels | 6/28/23 | 8/12/23 | Approved | Expanded Carrier Screening Panels |
2023-ACLA-2108 | Inherited Bone Marrow Failure Syndrome (IBMFS) Testing | 6/28/23 | 8/12/23 | Approved | Inherited Bone Marrow Failure Syndrome (IBMFS) Testing |
2023-ACLA-2109 | Inherited Thrombophilia Genetic Testing | 6/28/23 | 8/12/23 | Approved | Inherited Thrombophilia Genetic Testing |
2023-ACLA-2110 | Limb-Girdle Muscular Dystrophy Genetic Testing | 6/28/23 | 8/12/23 | Approved | Limb-Girdle Muscular Dystrophy Genetic Testing |
2023-ACLA-2111 | Liquid Biopsy Testing | 6/28/23 | 8/12/23 | Approved | Liquid Biopsy Testing |
2023-ACLA-2072 | Whole Genome Sequencing | 6/28/23 | 8/12/23 | Approved | Whole Genome Sequencing |
2023-ACLA-2073 | Afirma Thyroid Cancer Classifier Tests | 6/28/23 | 8/12/23 | Approved | Afirma Thyroid Cancer Classifier Tests |
2023-ACLA-2074 | All Map Gene Expression profiling for Heart Transplant Rejection | 6/28/23 | 8/12/23 | Approved | All Map Gene Expression profiling for Heart Transplant Rejection |
2023-ACLA-2075 | Allo Sure for Kidney Transplant Rejection | 6/28/23 | 8/12/23 | Approved | Allo Sure for Kidney Transplant Rejection |
2023-ACLA-2076 | Alpha-1 Antitrypsin Deficiency Testing | 6/28/23 | 8/12/23 | Approved | Alpha-1 Antitrypsin Deficiency Testing |
2023-ACLA-2077 | Amyotrophic Lateral Sclerosis (ALS) Genetic Testing | 6/28/23 | 8/12/23 | Approved | Amyotrophic Lateral Sclerosis (ALS) Genetic Testing |
2023-ACLA-2078 | Angelman Syndrome Testing | 6/28/23 | 8/12/23 | Approved | Angelman Syndrome Testing |
2023-ACLA-2079 | APOE Variant Analysis for Alzheimer disease Testing | 6/28/23 | 8/12/23 | Approved | APOE Variant Analysis for Alzheimer disease Testing |
2023-ACLA-2080 | Arrhythmogenic Right Ventricular cardiomyopathy Genetic Testing | 6/28/23 | 8/12/23 | Approved | Arrhythmogenic Right Ventricular cardiomyopathy Genetic Testing |
2023-ACLA-2081 | Ashkenazi Jewish Carrier Screening | 6/28/23 | 8/12/23 | Approved | Ashkenazi Jewish Carrier Screening |
2023-ACLA-2082 | Autism, Intellectual Disability, and Developmental Delay Genetic Testing | 6/28/23 | 8/12/23 | Approved | Autism, Intellectual Disability, and Developmental Delay Genetic Testing |
2023-ACLA-2083 | CADASIL Genetic Testing | 6/28/23 | 8/12/23 | Approved | CADASIL Genetic Testing |
2023-ACLA-2084 | Canavan Disease Genetic Testing | 6/28/23 | 8/12/23 | Approved | Canavan Disease Genetic Testing |
2023-ACLA-2085 | Charcot-Marie-Tooth neuropathy Testing | 6/28/23 | 8/12/23 | Approved | Charcot-Marie-Tooth neuropathy Testing |
2023-ACLA-2086 | CHARGE Syndrome Genetic testing | 6/28/23 | 8/12/23 | Approved | CHARGE Syndrome Genetic testing |
2023-ACLA-2087 | Chromosomal analysis for Blood and Bone Marrow Cancers | 6/28/23 | 8/12/23 | Approved | Chromosomal analysis for Blood and Bone Marrow Cancers |
2023-ACLA-2088 | Chromosomal Microarray for Developmental Disorders | 6/28/23 | 8/12/23 | Approved | Chromosomal Microarray for Developmental Disorders |
2023-ACLA-2089 | Chromosomal Microarray for Prenatal Diagnosis | 6/28/23 | 8/12/23 | Approved | Chromosomal Microarray for Prenatal Diagnosis |
2023-ACLA-2090 | Chromosomal Microarray for Solid Tumors | 6/28/23 | 8/12/23 | Approved | Chromosomal Microarray for Solid Tumors |
2023-ACLA-2091 | Chromosome Analysis for Reproductive Disorders, Prenatal Testing, and Developmental Disorders | 6/28/23 | 8/12/23 | Approved | Chromosome Analysis for Reproductive Disorders, Prenatal Testing, and Developmental Disorders |
2023-ACLA-2052 | MUTYH-Associated Polyposis Genetic Testing | 6/28/23 | 8/12/23 | Approved | MUTYH-Associated Polyposis Genetic Testing |
2023-ACLA-2053 | Myotonic Dystrophy Type 1 Genetic Testing | 6/28/23 | 8/12/23 | Approved | Myotonic Dystrophy Type 1 Genetic Testing |
2023-ACLA-2054 | NE Test | 6/28/23 | 8/12/23 | Approved | NE Test |
2023-ACLA-2055 | Neurofibromatosis Type 1 Genetic Testing | 6/28/23 | 8/12/23 | Approved | Neurofibromatosis Type 1 Genetic Testing |
2023-ACLA-2056 | Niemann-Pick Disease Type C Testing | 6/28/23 | 8/12/23 | Approved | Niemann-Pick Disease Type C Testing |
2023-ACLA-2057 | Niemann-Pick Disease Types A and B Testing | 6/28/23 | 8/12/23 | Approved | Niemann-Pick Disease Types A and B Testing |
2023-ACLA-2058 | Non-Invasive Prenatal Screening | 6/28/23 | 8/12/23 | Approved | Non-Invasive Prenatal Screening |
2023-ACLA-2059 | Non-syndromic Hearing Loss and Deafness Genetic Testing | 6/28/23 | 8/12/23 | Approved | Non-syndromic Hearing Loss and Deafness Genetic Testing |
2023-ACLA-2060 | Noonan Spectrum Disorder Genetic Testing | 6/28/23 | 8/12/23 | Approved | Noonan Spectrum Disorder Genetic Testing |
2023-ACLA-2061 | PALB2 Genetic Testing for Breast Cancer risk | 6/28/23 | 8/12/23 | Approved | PALB2 Genetic Testing for Breast Cancer risk |
2023-ACLA-2062 | Prader-Willi Syndrome Testing | 6/28/23 | 8/12/23 | Approved | Prader-Willi Syndrome Testing |
2023-ACLA-2063 | Spinocerebellar Ataxia Genetic Testing | 6/28/23 | 8/12/23 | Approved | Spinocerebellar Ataxia Genetic Testing |
2023-ACLA-2064 | Tay-Sachs Disease Testing | 6/28/23 | 8/12/23 | Approved | Tay-Sachs Disease Testing |
2023-ACLA-2065 | Thoracic Aortic Aneurysms and Dissections (TAAD) Panel Testing | 6/28/23 | 8/12/23 | Approved | Thoracic Aortic Aneurysms and Dissections (TAAD) Panel Testing |
2023-ACLA-2066 | ThyGeNEXT and ThyraMIR miRNA Gene Expression Classifier | 6/28/23 | 8/12/23 | Approved | ThyGeNEXT and ThyraMIR miRNA Gene Expression Classifier |
2023-ACLA-2067 | ThyroSeq | 6/28/23 | 8/12/23 | Approved | ThyroSeq |
2023-ACLA-2068 | Tissue of Origin Testing for Cancer of Unknown Primary | 6/28/23 | 8/12/23 | Approved | Tissue of Origin Testing for Cancer of Unknown Primary |
2023-ACLA-2069 | UroVysion FISH for Bladder Cancer | 6/28/23 | 8/12/23 | Approved | UroVysion FISH for Bladder Cancer |
2023-ACLA-2070 | VeriStrat Testing for NSCLC TKI Response | 6/28/23 | 8/12/23 | Approved | VeriStrat Testing for NSCLC TKI Response |
2023-ACLA-2071 | Von Hippel-Lindau Disease Genetic Testing | 6/28/23 | 8/12/23 | Approved | Von Hippel-Lindau Disease Genetic Testing |
2023-ACLA-2032 | Hypertrophic Cardiomyopathy Genetic Testing | 6/28/23 | 8/12/23 | Approved | Hypertrophic Cardiomyopathy Genetic Testing |
2023-ACLA-2033 | Immunohistochemistry (IHC) | 6/28/23 | 8/12/23 | Approved | Immunohistochemistry (IHC) |
2023-ACLA-2034 | Laboratory Claim Reimbursement | 6/28/23 | 8/12/23 | Approved | Laboratory Claim Reimbursement |
2023-ACLA-2035 | Legius Syndrome Genetic Testing | 6/28/23 | 8/12/23 | Approved | Legius Syndrome Genetic Testing |
2023-ACLA-2036 | Li-Fraumeni Syndrome Genetic Testing | 6/28/23 | 8/12/23 | Approved | Li-Fraumeni Syndrome Genetic Testing |
2023-ACLA-2037 | Long QT Syndrome Genetic Testing | 6/28/23 | 8/12/23 | Approved | Long QT Syndrome Genetic Testing |
2023-ACLA-2038 | Lyme Disease Testing | 6/28/23 | 8/12/23 | Approved | Lyme Disease Testing |
2023-ACLA-2039 | Lynch Syndrome Genetic Testing | 6/28/23 | 8/12/23 | Approved | Lynch Syndrome Genetic Testing |
2023-ACLA-2040 | Lynch Syndrome Tumor Screening Second-Tier | 6/28/23 | 8/12/23 | Approved | Lynch Syndrome Tumor Screening Second-Tier |
2023-ACLA-2041 | Macula Risk | 6/28/23 | 8/12/23 | Approved | Macula Risk |
2023-ACLA-2042 | Mamma Print 70-Gene Breast Cancer Recurrence Assay | 6/28/23 | 8/12/23 | Approved | Mamma Print 70-Gene Breast Cancer Recurrence Assay |
2023-ACLA-2043 | Marfan Syndrome Genetic Testing | 6/28/23 | 8/12/23 | Approved | Marfan Syndrome Genetic Testing |
2023-ACLA-2044 | Maturity-Onset diabetes of the Young Genetic Testing | 6/28/23 | 8/12/23 | Approved | Maturity-Onset diabetes of the Young Genetic Testing |
2023-ACLA-2045 | Medically Necessary Laboratory Testing | 6/28/23 | 8/12/23 | Approved | Medically Necessary Laboratory Testing |
2023-ACLA-2046 | Mitochondrial Disorders Genetic Testing | 6/28/23 | 8/12/23 | Approved | Mitochondrial Disorders Genetic Testing |
2023-ACLA-2047 | Microsatellite Instability and Immunohistochemistry Testing in Cancer | 6/28/23 | 8/12/23 | Approved | Microsatellite Instability and Immunohistochemistry Testing in Cancer |
2023-ACLA-2048 | Molecular Gastrointestinal Pathogen Panel (GIPP) Testing | 6/28/23 | 8/12/23 | Approved | Molecular Gastrointestinal Pathogen Panel (GIPP) Testing |
2023-ACLA-2049 | Molecular Respiratory Infection Pathogen Panel (RIPP) Testing | 6/28/23 | 8/12/23 | Approved | Molecular Respiratory Infection Pathogen Panel (RIPP) Testing |
2023-ACLA-2050 | Multiple Endocrine Neoplasic Type 1 Genetic Testing | 6/28/23 | 8/12/23 | Approved | Multiple Endocrine Neoplasic Type 1 Genetic Testing |
2023-ACLA-2051 | Multiple Endocrine Neoplasic Type 2 Genetic Testing | 6/28/23 | 8/12/23 | Approved | Multiple Endocrine Neoplasic Type 2 Genetic Testing |
2023-ACLA-2012 | Familial Hypercholesterolemia Genetic Testing | 6/28/23 | 8/12/23 | Approved | Familial Hypercholesterolemia Genetic Testing |
2023-ACLA-2013 | Familial Malignant Melanoma Genetic Testing | 6/28/23 | 8/12/23 | Approved | Familial Malignant Melanoma Genetic Testing |
2023-ACLA-2014 | Fibro Test. Fibro SURE | 6/28/23 | 8/12/23 | Approved | Fibro Test. Fibro SURE |
2023-ACLA-2015 | Flow Cytometry | 6/28/23 | 8/12/23 | Approved | Flow Cytometry |
2023-ACLA-2016 | FMR1-Related Disorders (Fragile X) | 6/28/23 | 8/12/23 | Approved | FMR1-Related Disorders (Fragile X) |
2023-ACLA-2017 | Friedreich Ataxia Genetic Testing | 6/28/23 | 8/12/23 | Approved | Friedreich Ataxia Genetic Testing |
2023-ACLA-2018 | Gene Sight Psychotropic Test | 6/28/23 | 8/12/23 | Approved | Gene Sight Psychotropic Test |
2023-ACLA-2019 | Genitourinary Conditions Molecular Testing | 6/28/23 | 8/12/23 | Approved | Genitourinary Conditions Molecular Testing |
2023-ACLA-2020 | Hemoglobinopathies Genetic Testing | 6/28/23 | 8/12/23 | Approved | Hemoglobinopathies Genetic Testing |
2023-ACLA-2021 | Hereditary Ataxia Multigene Panel Genetic Testing | 6/28/23 | 8/12/23 | Approved | Hereditary Ataxia Multigene Panel Genetic Testing |
2023-ACLA-2022 | Hereditary Cancer Syndrome Multigene Panels | 6/28/23 | 8/12/23 | Approved | Hereditary Cancer Syndrome Multigene Panels |
2023-ACLA-2023 | Hereditary Connective Tissue Disorder Testing | 6/28/23 | 8/12/23 | Approved | Hereditary Connective Tissue Disorder Testing |
2023-ACLA-2024 | Hereditary Pancreatitis Genetic Testing | 6/28/23 | 8/12/23 | Approved | Hereditary Pancreatitis Genetic Testing |
2023-ACLA-2025 | HFE Hemochromatosis Testing | 6/28/23 | 8/12/23 | Approved | HFE Hemochromatosis Testing |
2023-ACLA-2026 | HIV Tropism Testing for Maraviroc Response | 6/28/23 | 8/12/23 | Approved | HIV Tropism Testing for Maraviroc Response |
2023-ACLA-2027 | HLA Typing for Celiac Disease | 6/28/23 | 8/12/23 | Approved | HLA Typing for Celiac Disease |
2023-ACLA-2028 | Human Immunodeficiency Virus Laboratory Testing | 6/28/23 | 8/12/23 | Approved | Human Immunodeficiency Virus Laboratory Testing |
2023-ACLA-2029 | Human Papillomavirus (HPV) Molecular Testing | 6/28/23 | 8/12/23 | Approved | Human Papillomavirus (HPV) Molecular Testing |
2023-ACLA-2030 | Human Platelet and Red Blood Cell Antigen Genotyping | 6/28/23 | 8/12/23 | Approved | Human Platelet and Red Blood Cell Antigen Genotyping |
2023-ACLA-2031 | Huntington Disease | 6/28/23 | 8/12/23 | Approved | Huntington Disease |
2023-ACLA-1990 | Sleep Diagnostics | 6/28/23 | 8/12/23 | Approved | Sleep Diagnostics |
2023-ACLA-1991 | Sleep Disordered Breathing Diagnosis and Treatment General Guidelines | 6/28/23 | 8/12/23 | Approved | Sleep Disordered Breathing Diagnosis and Treatment General Guidelines |
2023-ACLA-1992 | Sleep Disordered Breathing Diagnosis and Treatment Place of Service | 6/28/23 | 8/12/23 | Approved | Sleep Disordered Breathing Diagnosis and Treatment Place of Service |
2023-ACLA-1994 | Criteria to Determine Medical Necessity for Skilled Physical-Occupational Therapy Care | 6/28/23 | 8/12/23 | Approved | Criteria to Determine Medical Necessity for Skilled Physical-Occupational Therapy Care |
2023-ACLA-1995 | Integumentary Considerations | 6/28/23 | 8/12/23 | Approved | Integumentary Considerations |
2023-ACLA-1996 | Lymphatic Considerations | 6/28/23 | 8/12/23 | Approved | Lymphatic Considerations |
2023-ACLA-1997 | Musculoskeletal Considerations | 6/28/23 | 8/12/23 | Approved | Musculoskeletal Considerations |
2023-ACLA-1999 | Pediatric Neurodevelopmental Considerations | 6/28/23 | 8/12/23 | Approved | Pediatric Neurodevelopmental Considerations |
2023-ACLA-2000 | Pelvic Considerations | 6/28/23 | 8/12/23 | Approved | Pelvic Considerations |
2023-ACLA-2001 | Swallowing and Feeding Considerations | 6/28/23 | 8/12/23 | Approved | Swallowing and Feeding Considerations |
2023-ACLA-2002 | Vestibular Considerations | 6/28/23 | 8/12/23 | Approved | Vestibular Considerations |
2023-ACLA-2003 | 4K Score for Prostate Cancer Risk Assessment | 6/28/23 | 8/12/23 | Approved | 4K Score for Prostate Cancer Risk Assessment |
2023-ACLA-2004 | BCR-ABL Negative Myeloproliferative Neoplasm Testing | 6/28/23 | 8/12/23 | Approved | BCR-ABL Negative Myeloproliferative Neoplasm Testing |
2023-ACLA-2005 | Bloom Syndrome Genetic Testing | 6/28/23 | 8/12/23 | Approved | Bloom Syndrome Genetic Testing |
2023-ACLA-2006 | BRCA Analysis | 6/28/23 | 8/12/23 | Approved | BRCA Analysis |
2023-ACLA-2007 | BRCA Ashkenazi Jewish Founder Mutation | 6/28/23 | 8/12/23 | Approved | BRCA Ashkenazi Jewish Founder Mutation |
2023-ACLA-2008 | Breast Cancer Index for Breast Cancer Prognosis | 6/28/23 | 8/12/23 | Approved | Breast Cancer Index for Breast Cancer Prognosis |
2023-ACLA-2009 | Brugada Syndrome Genetic Testing | 6/28/23 | 8/12/23 | Approved | Brugada Syndrome Genetic Testing |
2023-ACLA-2010 | Facioscapulohumeral Muscular Dystrophy Genetic Testing | 6/28/23 | 8/12/23 | Approved | Facioscapulohumeral Muscular Dystrophy Genetic Testing |
2023-ACLA-2011 | Familial Adenomatous Polyposis Genetic Testing | 6/28/23 | 8/12/23 | Approved | Familial Adenomatous Polyposis Genetic Testing |
2023-ACLA-1185 | Individual Placement and Support | 6/27/23 | 8/11/23 | Approved | Individual Placement and Support |
2023-LHCC-1962 | Provider Notifications | 6/27/23 | 8/11/23 | Approved | Provider Notifications |
2023-ACLA-1963 | Cranial Hair Prosthesis | 6/27/23 | 8/11/23 | Approved | Cranial Hair Prosthesis |
2023-ACLA-1964 | Custom Fabricated Devices | 6/27/23 | 8/11/23 | Approved | Custom Fabricated Devices |
2023-ACLA-1967 | Custom Fit DME | 6/27/23 | 8/11/23 | Approved | Custom Fit DME |
2023-ACLA-1969 | Mobility Power Wheelchair repairs and Replacement Accessories | 6/27/23 | 8/11/23 | Approved | Mobility Power Wheelchair repairs and Replacement Accessories |
2023-ACLA-1971 | Musculoskeletal Pediatric Foot Orthotics and Orthopedic Shoes | 6/27/23 | 8/11/23 | Approved | Musculoskeletal Pediatric Foot Orthotics and Orthopedic Shoes |
2023-ACLA-1972 | Musculoskeletal Spinal Orthoses | 6/27/23 | 8/11/23 | Approved | Musculoskeletal Spinal Orthoses |
2023-ACLA-1973 | Musculoskeletal Static Upper Extremity Orthoses | 6/27/23 | 8/11/23 | Approved | Musculoskeletal Static Upper Extremity Orthoses |
2023-ACLA-1974 | Replacement and Continued Use of DME | 6/27/23 | 8/11/23 | Approved | Replacement and Continued Use of DME |
2023-ACLA-1975 | Respiratory High Frequency Chest Wall Oscillation systems | 6/27/23 | 8/11/23 | Approved | Respiratory High Frequency Chest Wall Oscillation systems |
2023-ACLA-1977 | Skin and Wound Care Negative Pressure Wound Therapy | 6/27/23 | 8/11/23 | Approved | Skin and Wound Care Negative Pressure Wound Therapy |
2023-ACLA-1978 | Skin and Wound Care Pneumatic Compression Devices | 6/27/23 | 8/11/23 | Approved | Skin and Wound Care Pneumatic Compression Devices |
2023-ACLA-1979 | Standing Frames | 6/27/23 | 8/11/23 | Approved | Standing Frames |
2023-ACLA-1980 | Stimulators - Transcutaneous Electrical Nerve Stimulation | 6/27/23 | 8/11/23 | Approved | Stimulators - Transcutaneous Electrical Nerve Stimulation |
2023-ACLA-1982 | Indications Diagnostic Testing | 6/27/23 | 8/11/23 | Approved | Indications Diagnostic Testing |
2023-ACLA-1983 | Maintenance of Wakefulness Testing | 6/27/23 | 8/11/23 | Approved | Maintenance of Wakefulness Testing |
2023-ACLA-1985 | Pediatric Sleep Guidelines | 6/27/23 | 8/11/23 | Approved | Pediatric Sleep Guidelines |
2023-ACLA-1987 | PSG and Multiple Sleep Latency Testing | 6/27/23 | 8/11/23 | Approved | PSG and Multiple Sleep Latency Testing |
2023-ACLA-1988 | Repeat Sleep Testing | 6/27/23 | 8/11/23 | Approved | Repeat Sleep Testing |
Medicaid Managed Care Policies & Procedures Archive (2023) - Continued page 2
"Policy or procedure" shall mean a requirement governing the administration of managed care organizations specific to billing guidelines, medical management and utilization review guidelines, case management guidelines, claims processing guidelines and edits, grievance and appeals procedures and process, other guidelines or manuals containing pertinent information related to operations and pre-processing claims, and core benefits and services.
Below are items previously posted for public comment: